Phosphofructokinase (PFK) is clearly established as the enzyme catalyzing one of the principal rate controlling steps of glycolysis in virtually all tissues. The mechanism of regulation of this key pacemaker is a subject of continued interest, as mechanistic knowledge acquired in the study of this enzyme has general applicability to other allosteric enzymes. This continuing project will: (1) Study the allosteric regulatory properties and tissue distribution of phosphofructokinase-C, which is a major, unique isozyme of the brain. Among the properties to be examined are the kinetic consequence of protein phosphorylation, the regulatory role of fructose-2,6-P2, and the possible role of other regulatory ligands that may be important to the control of carbohydrate metabolism in the brain. As a part of these studies, monoclonal antibodies will be prepared against the A, B, and C isozymes of PFK. The antibodies will be used in isozyme isolation and in tissue distribution studies, and may provide tools for the isolation of homologous sequences among PFK isozymes. (2) Continue ongoing studies of the association of muscle PFK with F-actin, and to examine the role of PFK phosphorylation and the role of regulatory ligands on the binding phenomenon. (3) Extend studies of the tertiary structure and the multiple conformational forms of PFK by employing the technique of limited proteolysis coupled with primry structure analysis. (4) Study the kinetic consequences of the chemical modification of allosteric and catalytic sites, including modification of the AMP site with 2-azido-AMP, and modification of the ATP catalytic site with dialdehyde ATP, dialdehyde ITP, and 5[p-(fluorosulfonyl)benzoyl]adenosine. In each of these last instances the modified enzyme will be used in a parallel project to determine the complete covalent structure of PFK and to place these sites in the primary structure of the enzyme.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
5R01AM019912-10
Application #
3151266
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1978-05-01
Project End
1988-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
10
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Rosalind Franklin University of Medicine & Sci
Department
Type
Schools of Medicine
DUNS #
069501252
City
North Chicago
State
IL
Country
United States
Zip Code
60064
McCune, S A; Foe, L G; Kemp, R G et al. (1989) Aurintricarboxylic acid is a potent inhibitor of phosphofructokinase. Biochem J 259:925-7
Kemp, R G; Fox, R W; Latshaw, S P (1987) Amino acid sequence at the citrate allosteric site of rabbit muscle phosphofructokinase. Biochemistry 26:3443-6
Valaitis, A P; Foe, L G; Kemp, R G (1987) Desensitization of muscle phosphofructokinase to ATP inhibition by removal of a carboxyl-terminal heptadecapeptide. J Biol Chem 262:5044-8
Latshaw, S P; Bazaes, S; Randolph, A et al. (1987) Identification of highly reactive cysteinyl and methionyl residues of rabbit muscle phosphofructokinase. J Biol Chem 262:10672-7
Foe, L G; Kemp, R G (1985) Isolation and characterization of phosphofructokinase C from rabbit brain. J Biol Chem 260:726-30
Lin, J; Krishnaraj, R; Kemp, R G (1985) Exogenous ATP enhances calcium influx in intact thymocytes. J Immunol 135:3403-10